A Swiss microbiota biotherapeutics and mucosal vaccines company with two technology platforms: ApyraVax for the generation of innovative mucosal vaccines; ApyraMed with indication as enhancer in cancer immunotherapy and corrector of dysbiosis induced by antibiotic treatments and unhealthy diet.
- https://www.mv-bio.com/
- +41 58 666 72 25
- fgrassi@mv-bio.com
- Fabio Grassi